Research programme: leptin mimetics - AstraZeneca

Drug Profile

Research programme: leptin mimetics - AstraZeneca

Latest Information Update: 23 Dec 2009

Price : $50

At a glance

  • Originator Cambridge Biotechnology
  • Developer AstraZeneca
  • Class Small molecules
  • Mechanism of Action Leptin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 23 Dec 2009 AstraZeneca acquires leptin modulator programme for obesity from Biovitrum
  • 23 Nov 2009 Cambridge Biotechnology has been acquired by Proximagen Neuroscience
  • 09 Mar 2009 Leptin mimetic programme is available for out-licensing (http://www.biovitrum.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top